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Abstract
Tumors could evade the control of CD8+ T and/or NK cell-mediated surveillance by dis‐
tinct immune escape strategies. These include the aberrant expression of HLA class I anti‐
gens, coinhibitory or costimulatory molecules, and components of the interferon (IFN)
signal transduction pathway. In addition, alterations of the tumor microenvironment
could interfere with a proper antitumoral immune response by downregulating or inhib‐
iting the frequency and/or activity of immune effector cells and professional antigen pre‐
senting cells. Based on the identification as major mediators of the posttranscriptional
silencing of gene expression, microRNAs (miRNAs) have been suggested to play a key
role in many biological processes known to be involved in neoplastic transformation. In‐
deed, miRNA expression is frequently deregulated in many cancer types and could have
tumor-suppressive as well as oncogenic potential. This review focused on the characteri‐
zation of miRNAs, which are involved in the control of the immune surveillance or im‐
mune escape of tumors and their use as potential diagnostic and prognostic biomarkers
as well as therapeutic targets. Moreover, miRNAs can have dual activities by affecting the
neoplastic and immunogenic phenotype of tumors.
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1. Introduction
Tumors have developed different strategies to evade immune recognition by cytotoxic T
lymphocytes (CTLs) as well as natural killer (NK) cells. This is caused by alterations of the
tumor itself, changes of the tumor microenvironment (TME), reduced frequency, and impaired
function of diverse immune subpopulations. The processes leading to immune evasion of
tumors are diverse and could be associated with structural alterations and/or deregulation of
genes/proteins from tumor cells, but also from different immune cells important for recogni‐
tion and killing of tumor cells or in the induction of immune suppression. The identification
of microRNAs (miRNAs), involved in the RNA interference (RNAi)-based control of these
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immune modulatory molecules, clarified the complexity of the mechanisms conditioning
tumor immune escape. This review is focused on the identification and characterization of
immune modulatory miRNAs (im-miRNAs) in tumors, thereby altering the antitumoral
immune response by miRNAi-mediated RNAi.
2. The MHC class I antigen processing and presentation machinery (APM)
The major histocompatibility complex class I (MHC) molecules present an array of peptide
epitopes for surveillance by CD8+ T cells. These peptides are classically derived from proteins
synthesized in the cytosol. Upon proteasomal degradation of ubiquitinated proteins, the
yielded peptides are then transported into the endoplasmic reticulum (ER) via the heterodi‐
meric peptide transporter associated with antigen processing (TAP). The peptide transport
into the ER is ATP dependent and sequence specific. The TAP heterodimer associates in ER
with a number of other proteins to form the peptide loading complex (PLC). These include the
chaperone tapasin, which recruits MHC class I heavy chain (HC)/β2-microglobulin (β2-m)
dimers and calreticulin. The peptides are either trimmed by ER-resident aminopeptidases or
directly loaded onto MHC class I molecules [1]. Upon peptide loading, the PLC dissociates
from the trimer consisting of the MHC class I HC, β2-m, and peptide is then transported via
the trans Golgi to the cell surface and exposed to CD8+ CTLs [1].
3. Immune stimulatory and immune inhibitory molecules and immune
response
An effective T-cell response requires two signals. The first is mediated by the interaction with
MHC class I antigens on the antigen-presenting cells (APC), and the second is mediated by
the interaction of B7 family members on APC with CD28 or CTLA4 on T cells. The prototypes
of B7 family members are B7-1 (CD80) and B7-2 (CD86). During the last years, the B7 family
was growing consisting of B7-H1 (PDL-1), B7-H2, B7-H3, B7-H4, and B7-H6 molecules [2, 3].
While B7-H1 and B7-H4 represent coinhibitory molecules, B7-H2 was identified as costimu‐
latory molecule, which is mainly expressed on B cells, monocytes and dendritic cells (DC): B7-
H2 binds to the receptor ICOS, which results in activation of T cells through
phosphatidylinositol-3-kinase-dependent signal transduction pathways and in the induction
of Th2 cell-mediated immune response, proliferation, and cytokine production [4]. The role of
B7-H3 is currently controversially discussed and depends on the cell types analyzed, demon‐
strating either costimulatory or coinhibitory activity. Regarding B7-H4, its expression is
primarily restricted to activated T cells, B cells, monocytes, and DCs [5, 6]. B7-H4 is not detected
in the majority of normal tissues and cells but is overexpressed in a variety of tumor tissues.
B7-H6 has been identified as ligand for the NK cell receptor NKp30 and is detectable on surface
or in the cytosol of tumor cells and as soluble factor in the peritoneal fluid [7], while it is not
expressed on healthy cells. The interaction of B7-H6 with NKp30 is involved in NK cell
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responses [8]. It is noteworthy that many other coinhibitory molecules have also been identi‐
fied and their role on immune responses is currently under investigation [2, 3].
4. Features of the interferon-γ-mediated signal transduction
Interferons (IFN) are a group of pleiotropic cytokines that play a key role in the intercellular
communication during innate and adaptive immune responses, in particular in the host
defense against viral and bacterial infections and neoplastic transformation [9]. The IFN family
could be classified into type I and type II IFNs, which differ in their activity regarding immune
modulation [10].
IFN-γ belongs to the type II IFN and is a central regulator of immune responses by controlling
and modulating the expression of targets essential for cell-cell communication and cellular
interactions. It is secreted by activated T cells, NK cells, and macrophages and induced by DC
and monocytes stimulated with bacterial cell wall components [11]. IFN-γ exerts its activity
by binding to its heterodimeric receptor consisting of IFN-γ-R1 and IFN-γ-R2 subunits [12,
13]. This results in the dimerization of the receptor subunits followed by activation (trans‐
phosphorylation) of the receptor-associated tyrosine kinases JAK1 and JAK2 belonging to the
Janus kinase (JAK) family and phosphorylation and dimerization of the JAK-associated STAT1
transcription factor. The activated STAT1 is translocated into the nucleus and recruited to the
IFN-γ-activated sequence (GAS) element of the promoters of the STAT1 target genes leading
to their transcriptional activation.
IFN-γ-regulated genes can be classified into primary and secondary responsive genes. Primary
responsive genes are induced early due to the binding of STAT dimers to the GAS element in
the promoter region of target genes, like IRF1, CXCL9, and CXCL10 [14]. IRF1 binds to IFN-
stimulated response elements (ISRE) and modulates gene induction of the secondary respon‐
sive genes. IFN-γ induced the transcription of MHC class I and class II antigens and of many
APM components and at high concentrations could lead to a caspase-dependent apoptosis. In
addition, IFN-γ is involved in amplifying toll-like receptor (TLR) signaling by increasing or
inhibiting the transcription of TLRs, chemokines, and cytokines [15, 16]. Furthermore, IFN-γ
promotes the induction of SOCs proteins (suppressor of cytokine signaling), which inhibit IFN-
γ signaling by a negative feedback loop, resulting in the inactivation of JAK1 and JAK2 [17].
Moreover, IFN-γ signaling is controlled by inhibiting JAK1, JAK2, and IFN-γ-R1 via dephos‐
phorylation mediated by SH2-domain-containing protein tyrosine phosphatase 2 [18], by
proteasomal degradation of JAK1 and JAK2 [18] and by inhibition of STAT1, which is mediated
by the protein inhibitor of activated STAT1 [19].
5. Distinct levels of tumor immune escape
Tumors have developed different strategies to escape immune surveillance, which could occur
at the level of immune cells, tumor micromilieu, and the tumor itself (Figure 1). The frequency,
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activity, and function of CD8+ and CD4+ T lymphocytes, DC, NK cells, and B cells are often
downregulated in peripheral blood of tumor patients, while the number of immune-suppres‐
sive myeloid-derived suppressor cells (MDSC), NKT cells, and regulatory T cells (Treg) is
upregulated [20-23].
Figure 1. Tumor immune escape mechanisms containing (A) loss of tumor antigen expression; (B) variations in tumor
antigen processing; (C) defects in the peptide transporter TAP, chaperone tapasin, and protease ERAP1; (D) defects in
expression of MHC class I heavy chain and β2-microglobulin; (E) release of anti-inflammatory cytokines; (F) downre‐
gulation of IFN-γ-R1, JAK1, JAK2, STAT1, and STAT2; (G) altered phosphorylation states of STAT1; (H) impaired up‐
regulation of IFN-γ regulated genes (MHC class I, APM); (I) upregulated expression of HLA-G; (J) altered methylation
pattern of IRF; (K) overexpression of SOCS1; and (L) protection from T-cell-mediated apoptosis.
The tumor microenvironment (TME) consists of various cellular and soluble factors and is of
clinical relevance since its composition significantly correlates with the tumor patients’
outcome. These include different cellular components, such as fibroblasts, blood vessels,
immune cells, stroma cells, extracellular matrix, and soluble factors such as immune-suppres‐
sive cytokines, like interleukin (IL)-10, transforming growth factor (TGF)-β, metabolites,
arginase and prostaglandin, hypoxia, and pH, which negatively interfere with the antitumoral
immune responses.
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In tumors, an aggressive and deregulated growth of neoplastic transformed cells, which
overexpress proangiogenic factors, such as the vascular endothelial growth factor (VEGF),
leads to the development of organized blood vessels. These blood vessels are fundamentally
different from the normal vasculature. Tumor-associated fibroblasts (TAF) represent the major
constituents of the tumor stroma and produce growth factors, including the VEGF and
inhibitory cytokines that activate extracellular matrix thereby contributing to the tumor
growth.
Furthermore, cancer is often driven by inflammation mediated by monocytes and tumor-
associated macrophages (TAM), which belong to the innate immune cells. Macrophages could
be classified in type 1 and 2 macrophages. While M1 macrophages express a series of proin‐
flammatory cytokines, chemokines and effector molecules, the M2 macrophages express a
wide array of anti-inflammatory molecules, including IL-10, IL-35, TGF-β, and adenosine.
TAMs are mainly of the M2 phenotype and secrete different cytokines, chemokines and
proteases, which promote tumor angiogenesis, growth, metastasis as well as immune sup‐
pression.
In addition to TAM and TAF, MDSC represent a heterogeneous population derived from
myeloid progenitors [20]. They can promote tumor growth by enhancing angiogenesis or
suppression of innate and adaptive immune responses. Regarding the innate immune cells,
MDSCs  suppress  NK  cell  cytotoxicity,  promote  M2  macrophage  differentiation,  and
modulate  the  priming  activity  of  mature  DC  [24].  Moreover,  MDSCs  suppress  T-cell
responses by induction of apoptosis, secretion of immune modulatory factors, modulation
of amino acid metabolism, restriction of T-cell homing, and induction of Treg [25-28]. Tregs
suppress the activity of immune cells and maintain immune tolerance to self-antigens. They
express CD4, CD25 and FoxP3 [22]. The elevated numbers of Tregs in cancer is due to their
efficient migration into the tumor sites [29], local expansion in the tumor environment[29],
and de novo generation within the tumor [30].
5.1. Alterations of the tumors
Immune escape mechanisms include loss or downregulation of HLA class I antigens and/or
components of the antigen processing machinery (APM), upregulation of nonclassical HLA-
G and HLA-E antigens, and coinhibitory molecules, including PDL-1, as well as alterations of
signaling transduction cascades, including in particular the IFN signaling pathway [31]. The
frequency of these different mechanisms highly varied between tumor (sub)types and is often
correlated with a worse prognosis and reduced survival of tumor patients.
5.1.1. MHC class I abnormalities
The classical MHC class I pathway and the APM components are involved in eradication of
developing tumors [32]. Since CD8+ CTLs recognize and eliminate cells presenting tumor
antigens via HLA class I molecules, loss of HLA class I expression results in evasion of CTL-
mediated cell death [33]. Abnormalities of HLA class I antigens are often due to downregula‐
tion of various components of the MHC class I APM, in particular of TAP, tapasin, β2-m, and
MHC class I HC. Structural alterations of these components are rare, while MHC class I defects
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are mainly due to deregulation of the different components, which could be controlled at the
transcriptional, epigenetic (methylation, acetylation), posttranscriptional (e.g., microRNAs,
protein degradation), or posttranslational (phosphorylation) level.
HLA-G has been demonstrated as a nonclassical HLA class I antigen, which is in general only
expressed on immune privileged organs, but also on many tumors of distinct origin [34]. The
overexpression of HLA-G or secretion of soluble HLA-G are directly associated with tumor
progression and reduced patients’ survival. It suppresses antitumoral immune responses by
binding to receptors of various immune populations, thereby inhibiting the sensitivity to CTL-
and NK cell-mediated lysis in particular [34]. In contrast, tumor cells with deficient expression
of classical HLA class I molecules are eradicated by NK cells.
5.1.2. Check points as important regulators of immune response
During carcinogenesis, members of the B7-family play a key regulatory role of both stimulato‐
ry and inhibitory T-cell responses, which depends on the available B7 ligand and receptor on
the respective target and immune cells [35, 36]. Interestingly, B7-H1 and B7-H4 were often
overexpressed on tumors leading to impaired immune recognition. By interaction with these
coinhibitory molecules, the intensity of the T-cell responses is reduced by raising the thresh‐
old of activation, halting proliferation, enhancing apoptosis, and inhibiting the differentia‐
tion of effector cells [37].
5.1.3. Role of IFN-γ in cancer immunogenicity
Abnormalities of MHC class I expression on tumor cells due to the downregulation or loss of
APM component expression are common mechanisms, by which tumor cells can escape from
anti-tumor-specific immunity [38, 39]. In addition, tumor cells are often not susceptible to
treatment with IFN-γ, which could be due to structural alterations or deregulation of constit‐
uents of the IFN signal pathway. Several studies confirmed that defects in the IFN-γ receptor
signaling cascade could be occur at multiple steps of this pathway, including lack of the
expression of the IFN-γ-R1, abnormal forms of JAK2, lack of expression of JAK1 [40], altered
phosphorylation, repressed STAT1 expression, and overexpression of SOCS1. The latter results
in an increased negative feedback regulation of the IFN-γ signal cascade. The defects in the
IFN-γ receptor signaling cascade caused impaired expression of IFN-γ regulated genes.
Previous studies demonstrated that IFN-γ responsive genes are frequently downregulated in
tumor cells due to impaired IRF1 expression as well as defective transcriptional and posttran‐
scriptional regulation of components involved in the IFN-γ signal transduction pathway. The
loss of the IFN-γ-mediated upregulation of TAP in a renal cell carcinoma is associated with
the lack of IRF1 and STAT1 binding activities as well as JAK1, JAK2, and STAT1 phosphory‐
lation [41]. This impaired IFN-γ-mediated phosphorylation could not be restored by JAK1 and/
or JAK2 gene transfer. Furthermore, an impaired STAT1-phosphorylation associated with the
loss of IFN-γ-mediated MHC class I upregulation was also reported in melanoma and
colorectal carcinoma cells [42].
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IFN-γ treatment is able to restore the expression of many genes belonging to the MHC class I
APM [43, 44]. As a consequence, anti-tumor-specific immune responses can be induced,
suggesting that IFN-γ acts as key regulator of immunogenicity [45]. Its antitumoral activity
includes also the induction of apoptosis and inhibition of cell proliferation by STAT1 activa‐
tion, which induces expression of cell cycle inhibitor, CDKN1A [46]. In addition, the IFN-γ-
mediated upregulation of MHC class I antigens could be due to DNA demethylation of MHC
class I APM genes, suggesting that IFN-γ acts as an epigenetic modifier of APM components
[47]. Therefore, IFN-γ is a major player in the regulatory network combating tumor cell
proliferation and tumor survival.
6. Features of miRNAs
miRNAs are small noncoding ~22 nucleotide long regulatory RNAs encoded in the human
genome,  which  control  the  posttranscriptional  gene  expression  by  binding  to  the  3′-
untranslated region (UTR) of mRNA of target genes, thereby affecting their stability and/or
their translation [48]. An individual miRNA could target numerous cellular mRNAs, while
single miRNA can be regulated by several proteins [49, 50]. miRNAs have emerged as key
players  in  the  posttranscriptional  control  of  gene expression and based on their  predic‐
tion appear to be directly involved in the expression of at least 50% of all protein-coding
genes in mammals [51].
A strong relationship between miRNAs and human cancer has been developed during the past
years. High throughput analysis allows the comparison of miRNA expression pattern in
normal and tumor tissues demonstrating global changes within the miRNA expression in
different malignancies. Interestingly, the miRNA genes were frequently located at fragile sites
and cancer-associated chromosomal regions. The deregulation of the biogenesis and expres‐
sion of miRNAs is involved in the initiation as well as progression of tumors, metastasis
formation, and therapy resistance [52]. Furthermore, miRNAs can participate in reprogram‐
ming components of the tissue tumor microenvironment (TME) in order to promote tumor‐
genicity [53]. In the following sections, miRNAs are described as powerful RNAi inducing
regulators of immune modulatory genes involved in escape from immune surveillance.
Moreover, this review highlights some miRNAs and their roles in immune escape and
discusses these miRNAs as putative targets for (immune) therapy (Figure 2).
6.1. Antigen processing and presentation machinery and miRNAs
Recent studies showed identified miRNAs able to affect the expression of APM components.
Microarray analysis of miRNA-9 overexpressing nasopharyngeal carcinoma cells demonstrat‐
ed that miRNA-9 controls the expression of components of the classical MHC class I pathway.
miRNA-9 targets many IFN-induced genes and MHC class I APM molecules, such as the
proteasome subunits PSMB8 and PSMB10, TAP1, β2-m, HLA-B, HLA-C, and the nonclassical
HLA-F and HLA-H antigens [54]. However, the binding of miRNA-9 to the 3′-UTR of these
molecules has not yet been shown. miRNA-9 is involved in the cellular differentiation [55] and
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aberrantly expressed in many cancer types breast cancer[56], colon cancer [57], nasopharyng‐
eal carcinoma [58], and melanoma [59], suggesting that the decreased miRNA-9 expression is
associated with tumor suppressor activity. In contrast, miRNA-9 expression is increased in
brain cancer [60] and in Hodgkin’s lymphoma [61], implying an oncomir potential. Further‐
more, miRNA-9 has been shown to regulate the proliferation [56, 60-62] epithelial-mesenchy‐
mal transition (EMT), invasion and metastasis [62-64], apoptosis [56], tumor angiogenesis
[63-64], and evasion of immune surveillance in many cancer types [54]. Although the function
of miRNA-9 in the classical MHC class I pathway has still to be characterized in extent,
miRNA-9-mediated regulation of APM deficiencies might be at least partially responsible for
the T cell-mediated immune escape.
Besides miRNA-9, the ER stress-induced miRNA-346 modulates the expression of APM
components and IFN-induced genes as shown by miRNA arrays. Functional studies revealed
that TAP1 is a direct target of miRNA-346 using overexpression and RNAi knockdown
experiments with miRNA mimic and miRNA inhibitors. The ER stress-mediated MHC class
I-associated antigen presentation decrease might be explained by increased miRNA-346
expression [65], although the function of miRNA-346 in cancer has not yet been fully analyzed.
The inflammation and overexpression of miRNA-451 are associated with the carcinogenesis
of lung cancer. A decrease in the proliferation, invasion, and metastatic potential of lung cancer
cells was detected after the overexpression of miRNA-451. In addition, the proteasome subunit
Figure 2. Scale of miRNAs targeting immune pathways in cancer exhibit an imbalance of tumor-suppressive miRNAs,
which occur more frequent than oncogenic miRNAs as per knowledge from today. Oncogenic miRNA are highly ex‐
pressed in cancer, while tumor-suppressive miRNAs possess a reduced expression.
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PSMB8 has been identified as a direct target of miRNA-451 using both bioinformatics and dual
luciferase reporter assays. This was confirmed by miRNA-451-overexpressing lung cancer
cells, demonstrating a reduced PSMB8 protein expression. These data suggest that miRNA-451
inhibits the development and metastasis of lung cancer [66].
There  are  variations  that  exist  in  the  3′-UTR  of  HLA-C,  which  modulate  the  miRNA-
binding  capacity  and  consequently  the  HLA-C  surface  expression.  miR-148a  has  been
shown  to  bind  to  the  HLA-C  3′-UTR.  Next  to  cancer,  the  miRNA-148a  expression  is
associated with the control  of  HIV [67-70].  Furthermore,  miRNA-181a is  upregulated in
Hepatitis B virus infected cells and has a binding site in the 3′-UTR of the HLA-A gene,
which might be a target of miRNA-181a [71].  Moreover, viral DNA or RNA can encode
miRNAs, e.g., miRNA-US4-1 from the human cytomegalovirus, which targets the amino‐
peptidase ERAP1, thereby blocking CTL response [72].
6.2. Control of HLA-G and MHC-related proteins by miRNAs
Recently, a number of HLA-G-specific miRNAs have been identified, which belong to the
miRNA-148 family consisting of three members, miRNA-148a, miRNA-148b, and miRNA-152.
These miRNAs have been shown to act as tumor suppressors in many tumors, including
prostate, ovarian, endometrial, and colorectal cancer [69, 73, 74]. In addition, other miRNAs
such as miRNA-133, miRNA-548, and miRNA-628 have been identified to inhibit HLA-G
expression. The HLA-C-regulating miRNAs are involved in inducing T and/or NK cell
responses and have a tumor-suppressive capacity. Moreover, some of the HLA-G-regulated
miRNAs are inversely expressed when compared to HLA-G in tumor lesions and are associ‐
ated with disease progression [74].
The cytotoxicity of NK cells is determined by activating and inactivating signals. The ligands
of the activating NK cell receptor NKG2D are the major histocompatibility complex class I-
related molecules (MIC) A and B and the human cytomegalovirus UL16-binding proteins
(ULBP) [73]. The expression of MICA and MICB is controlled by several oncogenic miRNAs,
like miRNA-10b, miRNA-17-5p, miRNA-20a, miRNA-25, miRNA-93, and miRNA-106b,
which increase the proliferative, invasive, and angiogenic potential of tumors [73, 75-83] and
affect the NK cell cytotoxicity. The tumor-suppressive miRNA-302c, miRNA-376a, and
miRNA-433-3p showed a reduced expression in cancer and target the 3′-UTR of MIC [73,
84-87]. Furthermore, the expression of ULBP is regulated by many tumor-suppressive
miRNAs, e.g., miRNA-34a/c, miRNA-140-5p, miRNA-302c, miRNA-409-3p, and miRNA-433-
p, and by the oncogenic miRNA-650 [73, 83, 85, 87].
6.3. Control of B7 family members by miRNA
The expression of B7 family members is subject to the regulatory control of miRNAs: B7-H1
could act as a costimulatory molecule, which is expressed on B cells, T cells, macrophages, and
DCs [88], and acts as a ligand for PDL-1. miRNA-513 targets B7-H1 and inhibits its expression
by translational repression [89]. In this context, Tamura and coworkers identified an associa‐
tion between low expression of B7-H2 and the escape from immune surveillance indicating
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that B7-H2 has a potential role in tumorigenesis. B7-H2 [90] is a direct target of miRNA-24,
which inhibits B7-H3 expression and therefore is involved in cancer immune evasion. B7-H3
is an immune regulatory molecule, which is often overexpressed in different cancers and
associated with metastasis and poor prognosis [91, 92]. Its expression could be posttranscrip‐
tionally regulated by miRNA-29c. The miRNA-29c-mediated downregulation of B7-H3
expression was found in breast cancer and acts therefore as tumor-suppressive miRNA [93].
Furthermore, another B7-H3-regulating miRNA, miRNA-187, has been identified in clear renal
cell carcinoma, and its expression is downregulated in this disease [94]. The coinhibitor B7-H4
functions as a negative mediator of immune responses. So far, no information exists about the
role of miRNAs in the regulation of B7-H4 expression. In addition, miRNAs binding to the 3′-
UTR of B7-H6 have not yet been identified.
6.4. Control of the IFN-γ pathway by miRNAs
The regulation of IFN-γ signaling includes negative as well as positive regulators, such as
kinases and phosphatases as well as transcription factors. A main regulatory role of IFN-γ
signaling is attributed to miRNAs, affecting genes involved in proliferation, differentiation,
signal transduction, immune response, and carcinogenesis [50, 95].
IFN-γ can modulate the expression levels of miRNAs and to regulate miRNAs at the level of
miRNA biogenesis [96], whereas miRNAs can inhibit IFN expression directly or indirectly. In
addition, studies have confirmed that miRNAs are able to target components of the IFN-γ
signaling pathway and components of the JAK/STAT-pathway can regulate miRNAs simul‐
taneously. The latter has been described by controlling miRNA expression via transcription
factors, such as c-myc, the hypoxia-induced factor (HIF), and STATs [97]. The contribution and
regulatory role of miRNAs in IFN-γ signaling is still under investigation and an emerging
research area. Here, to highlight the regulatory function of miRNAs in the IFN-γ signaling
pathway, the functional role of miRNA-155 has been described in more detail.
miRNA-155 proceeding from the non-protein-coding transcript of the BIC gene RNA is
required for the normal function of B, T, and DC [98. 99], and its expression is increased during
B cell, T cell, macrophage, and DC activation [100]. miRNA-155 has been shown to regulate
IFN-γ production in NK cells, while its disruption or knockdown suppressed IFN-γ induction
of NK cells [101]. Additional studies reported that miRNA-155 also downregulates IFN-γ-R
expression [102]. Furthermore, STAT1 upregulates miRNA-155, which in turn downregulates
SOCS1, a negative inhibitor of JAK1 [103]. These findings illustrate that a single miRNA can
regulate several target mRNAs of the IFN cascade and miRNAs can be regulated by a number
of targets.
miRNA regulating components of IFN-γ signaling pathway mainly act as tumor-suppressive
miRNAs. An antiproliferative effect of miRNA-375, which affects JAK2 protein expression,
has been recently described [104, 105]. Furthermore, miRNA-135a expression was downregu‐
lated in gastric cancer cell lines, while its overexpression results in inhibition of gastric cancer
cell proliferation by targeting JAK2 [106]. Thus, miRNA-135a may function as tumor suppres‐
sor by regulating JAK2 expression in gastric cancer cells [107]. Several studies confirmed other
miRNAs targeting JAK2, including miRNA-216a, which is known to inhibit cell growth and
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promote apoptosis of pancreatic cancer cells by regulating JAK2/STAT3 signaling pathway
[108, 109], as well as miRNA-101, which promotes apoptosis of breast cancer cells by targeting
JAK2 [110]. Similar results were found for STAT1 and miRNA-145 [111]. miRNA-145 is
reported to be downregulated in several cancers [112, 113] and has STAT1 as direct target [111].
Moreover, STAT1 is able to upregulate miRNA-29 family members in melanoma cells, which
inhibit melanoma cell proliferation by downregulating CDK6 [114].
Further studies confirmed that miRNA-223 and miRNA-150 are equally involved in IFN-γ
signaling, but their role in cancer cells is still controversially discussed. Both miRNA-150 and
miRNA-223 could exert oncogenic or tumor-suppressive activity. In hepatocellular carcinoma,
acute myeloid leukemia (AML) [115] and gastric mucosa-associated lymphoid tissue lympho‐
ma miRNA-223 expression is repressed [116], while an upregulation of miRNA-223 has been
recently described in T-cell acute lymphocytic leukemia (T-ALL) [117]. In this context, Moles
and coworkers [118] demonstrated that both miRNA-223 and miRNA-150 target STAT1 3′-
UTR and reduce STAT1 expression, which in turn results in reduced expression of IFN-γ-
regulated genes. The expression of miRNA-150 is upregulated in CD19+ B cells from chronic
lymphocytic leukemia [119, 120], while in chronic myeloid leukemia [121, 122], ALL [123] and
mantel cell carcinoma miRNA-150 is downregulated. Moreover, miRNA-150 is upregulated
in adult T-cell leukemia/lymphoma cells. This discrepant expression pattern of miRNA-223
and miRNA-150 suggests that both miRNAs could act as oncogenic as well as tumor suppres‐
sor miRNAs, which are dependent on the cellular context.
6.5. Role of miRNAs in immune cell function
Cancer cells upregulate and downregulate different miRNAs in immune cells to limit the
antitumor response. It is well known that tumor cells reprogram the myeloid compartment to
evade the immune system and promote tumorigenesis. This might be partially mediated by
alterations in the miRNA expression pattern. The miRNA-155 modulates the immune response
mediated by T cells, NK cells, B cells, and antigen presenting cells, such as macrophages and
DC [124]. Furthermore, miRNA-155 expression has been found to be downregulated in TAMs
[125], but also in hepatocellular carcinoma. The restoration of miRNA-155 in macrophages
leads to enhanced T-cell function by targeting the suppressor of cytokine signaling. Other
miRNAs, like miRNA-142-3p, miRNA-125b, and miRNA-19a-3p, are often downregulated in
TAMs, thereby limiting the tumor infiltration of macrophages and reducing the therapeutic
effect of adoptive transfer. The restoration of miRNA-125b in macrophages enhances antitu‐
mor response by targeting the IFN-regulatory factor 4, which promotes the M2 macrophage
phenotype [126].
Recently, miRNAs have been identified to play a role in MDSC that regulate immune sup‐
pression within the tumor microenvironment. miRNA array analysis identified a number of
deregulated miRNAs, e.g., miRNA-494, which suppresses the antitumor CD8+ T-cell responses
due to response to TGF-β. miRNA-494 targets PTEN in MDSC, which is responsible for the
enhanced immune suppression of CD8+ T cells [127]. Furthermore, a number of other miRNAs
are downregulated in MDSC [128], which promote the differentiation of myeloid cells and
regulate immune-suppressive signaling pathways.
The Role of Immune Modulatory MicroRNAs in Tumors
http://dx.doi.org/10.5772/61805
47
In addition, miRNAs have been demonstrated in tumor-infiltrating lymphocytes. The sup‐
pression of T-cell activity is due to different mechanisms, including the dysregulation of
miRNA expression. In CD4+ T cells from tumor bearing mice and tumor patients, the expres‐
sion of miRNA-17-92 family members was reduced, while T cells derived from miRNA-17-9
transgenic mice demonstrated a superior type 1 phenotype [129]. Furthermore, the expression
of miRNA-155 was shown to promote antitumor responses. miRNA-155 in combination with
miRNA-146a could upregulate the IFN-γ production of T cells. Furthermore, cancer cells could
regulate miRNAs in T cells in order to modulate antitumor T-cell responses. In order to escape
immune surveillance, cancer cells alter the expression of transcription factors, surface recep‐
tors, soluble chemokines/cytokines, and miRNAs to support the immune system. The down‐
regulation of miRNA-124 increases Treg infiltration and reduces cytokines production through
an altered expression of STAT3, which represents a target of miRNA-124. In contrast, tumor-
secreted miRNA-214 induces Treg. Regarding NK cells, the TGF-β-inducible miRNA-183
affects NK cell activity [130]. Thus, the regulation of miRNAs within the cancer cell alters the
TME through manipulation.
7. Conclusion and future perspectives
Taken together, during the past years, the posttranscriptional control of gene expression by
miRNAs has gained relevance as key regulator in a wide variety of physiological and pathophy‐
siological processes due to the role of miRNA-mediated RNAi not only in differentiation,
proliferation, apoptosis, immune responses but also in viral and bacterial infections as well as
neoplastic transformation (Table 1). A deregulated expression of miRNAs has been often found
in tumors of distinct origin, which have been classified into oncogenic or tumor-suppressive
miRNAs known to play an essential role in cancer initiation and progression. Therefore, these
miRNAs could act as potential biomarkers and therapeutic targets in cancer. In silico predic‐
tion analysis further proposed that many miRNAs could target different immune modulato‐
ry molecules expressed either on tumor cells or on different immune cell subpopulations.
As summarized, an emerging relevance of miRNAs in mounting the tumor immune escape
by altering the communication between cancer cells, immune cells, and other components of
the TME has been demonstrated. This leads to another level of complexity due to the involve‐
ment of miRNAs in the interaction between cancer cells and immune cells. These miRNAs
might not only provide new insights into tumor growth and progression as well as antitumoral
immune responses but also represent promising therapeutic targets for (immune) therapy. To
date, many cancer-deregulated miRNAs have been identified in particular in cancer cells and
also in components of the TMA. However, their role in modulating the antitumor immune
responses has not yet been characterized in detail. Although the majority of the miRNA
alterations detected are dedicated to cancer cells, there is already evidence that miRNAs of
infiltrating immune cells also particularly influence tumorgenicity. The identification of
further im-miRNAs as well as their functional characterization might lead to a plethora of
novel candidate biomarkers for monitoring of immune responses, which might be also
potentially used for targeted RNAi therapy.
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Table 1. Identified miRNAs involved in the tumor immune escape and their tumor–associated function.
Controversially discussed miRNAs are found as tumor suppressors in some cancer types, while exhibiting oncogenic
properties in other cancer types. n.d., no data.




APC, antigen presenting cell; APM, antigen processing machinery; β2-m, β2-microglobulin;
CDKN, cyclin-dependent kinase inhibitor; CTL, cytotoxic T lymphocyte; CXCL, chemokine
(CXC motif) ligand; DC, dendritic cell; GAS, IFN-γ-activated sequence; HC, heavy chain; HLA,
human leukocyte antigen; IFN, interferon; IL, interleukin; IRF, interferon regulatory factor;
ISRE, IFN-stimulated response element; im-miRNA, immune modulatory miRNA; JAK, janus
kinase; LMP, low molecular mass polypeptide; MAPK, MAP kinase; MDSC, myeloid-derived
suppressor cell; MHC, major histocompatibility complex; MIC, major histocompatibility
complex class I-related molecule; miRNA, microRNA; NK, natural killer cell; PD, programmed
death; PDL, PD ligand; PLC, peptide loading complex; STAT, signal transducer and activator
of transcription; SOCS, suppressor of cytokine signaling; TAF, tumor-associated fibroblast;
TAM, tumor-associated macrophage; TAP, transporter associated with antigen processing;
TGF, transforming growth factor; TLR, toll-like receptor; TME, tumor microenvironment;
Treg, regulatory T cell; ULBP, human cytomegalovirus UL16-binding protein; UTR, untrans‐
lated region; and VEGF, vascular endothelial growth factor.
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